Antibody reduced small-vessel heart damage in mice
An antibody improved the heart’s inner lining and increased small-vessel density in mice with mutant blood cells fed a high-fat, high-cholesterol diet for five weeks.

Our read
Mechanisms- Studied:
- Experiments in JAK2V617F mutant mice, five weeks, against HFD treatment alone
- What changed:
- Perivascular collagen fibrosis was reduced in antibody-treated mice compared to mice on high-fat diet alone
- The catch:
- Only 6–8 mice per group were analyzed
Editor of record: Boris Djordjevic · AgingResearch.News
Mice in an animal experiment received bone marrow carrying JAK2V617F, a mutation affecting blood-cell production. Their blood-vessel lining cells remained normal. After five weeks on a high-fat, high-cholesterol diet, they developed narrowed small heart arteries, scarring around vessels and damage to the heart’s inner lining.
Researchers tested an antibody against MPL, a receptor involved in blood-cell production. They gave it intravenously at 0.1 milligrams per kilogram every 10 days for four doses during the five-week diet. Compared with mutant mice on the diet alone, antibody-treated mice had less heart-vessel damage and increased small-vessel density. The antibody also restored the integrity of the heart’s inner lining. It did not alter blood counts.
Why it matters
The study addresses how altered blood cells can damage small heart vessels, a question relevant to cardiovascular health in aging. The authors proposed signaling through this receptor as a potential target for cardiovascular disease linked to the mutation.
Caveats
These results came from a bone-marrow-transplant mouse model under dietary stress, not from people. Male and female results were combined, and sex differences were not assessed.
From the paper
- Animals
To account for the variability in coronary arteriole morphology across treatment conditions, 6–8 mice were analyzed per group, with approximately 70–100 microvessels evaluated in each group.
- Follow-up
Peripheral blood platelet counts remained stable throughout a 14-day follow-up period.
Quoted word for word from the full text on PubMed Central.
The paper
Targeting Thrombopoietin/MPL Signaling to Mitigate JAK2V617F-Driven Cardiac Microvascular Disease
Peking Union Medical College Hospital; Stony Brook School
Arteriosclerosis, Thrombosis, and Vascular Biology, Sep 3, 2026, Open access, accepted manuscript



Comments
Be the first to comment.